Difference between revisions of "Statistical Computing Environments"

From PHUSE Wiki
Jump to: navigation, search
(Upcoming Deliverables and Dates:)
(Upcoming Deliverables and Dates:)
Line 35: Line 35:
| Publish final white paper with SCE use cases || Mar, 2016
| Publish final white paper with SCE use cases || Mar, 2016
=State of the SCE White Paper=
=State of the SCE White Paper=

Revision as of 08:44, 17 May 2016

Project Title

Statistical Computing Environments (SCEs)

Project Leads

Name Role Organization E-mail
Art Collins Lead Biogen arthur.collins@biogen.com
Stephen Matteson Co-lead Pfizer stephen.p.matteson@pfizer.com
Nigel Montgomery Co-lead Novartis nigel.montgomery@novartis.com

Affected Stakeholders

Could include statisticians, clinical reviewers, nonclinical reviewers, software developers, SDO, etc.

Definition(s) of Problem/Issue/Challenge

This project came about because of a common set of challenges facing organizations across the industry around Statistical Computing Environments (SCEs). The group has four objectives:

  1. Discuss the current state of SCEs, identify common gaps and share best practices
  2. Define ideal case user requirements for an SCE
  3. Clarify expectations for an SCE within industry and regulatory agencies regarding implementation and compliance
  4. Explore SCE relationship to the Metadata Repository (MDR) and the Clinical Data Repository (CDR)

Upcoming Deliverables and Dates:

Deliverable Date
SCE Stream at PhUSE European CS Working Group Meeting 21 June, 2016
Publish draft white paper with SCE use cases Dec, 2016
Publish final white paper with SCE use cases Mar, 2016

State of the SCE White Paper

'The State of the SCE' published 29Apr2016.

Recommended Reading

Regulatory Guidance:

FDA, 21 CFR Part 11, Electronic Records; Electronic Signatures; Final Rule. Federal Register Vol. 62, No. 54, 13429, March 20, 1997

FDA, Guidance for Industry - Part 11, Electronic Records; Electronic Signatures - Scope and Application, August 2003

FDA, Guidance for Industry - Computerized Systems Used in Clinical Trials, April 1999

FDA, Guidance for Industry - Computerized Systems Used in Clinical Investigations, May 2007


Date/Time Stamped Files and Audit Trails: What Part 11 Compliant SAS® Systems are Made of, Carolyn Dougherty, ViroPharma Incorporated, Exton, PA, NESUG 16 Paper

BUILDING A CONTROLLED STATISTICAL PROGRAMMING ENVIRONMENT, Wayne Woo, Novartis Vaccines & Diagnostics, Cambridge, MA, WUSS 13 Paper

Standards-based, Metadata-driven Statistical Computing Environments, Sue Dubman, September 28, 2010, PhUSE, Cambridge, MA

Hopkins, Duke, Dubman, "Statistical Computing Environments and the Practice of Statistics in the Biopharmaceutical Industry", Drug Information Journal, Vol. 44, 2010

Statistical Computing Environment Implementation – An Agile Approach, Gary Cozzolino, d-Wise Technologies, Morrisville, NC, PharmaSUG 2013 - Paper MS12

Building a Hosted Statistical Computing Environment: Is it Possible?, d-Wise

d-Wise's View of Clinical Data Repositories (CDRs) – 2013, Posted by Keith Ward on Aug 29, 2013

The Solution Landscape Part 3: SCE., Posted by Keith Ward on Oct 3, 2013

The Submission Data File System - Automating the Creation of CDISC SDTM and ADaM Datasets, Marcus Bloom, Amgen, David Edwards, Amgen, PhUSE 2006

MACUMBA: Modern SAS® GUI Debugging Made Easy, Michael Weiss, Bayer Pharma AG, SAS Global Forum 2013

Last revision by Collinsa,05/17/2016